Furthermore, we found that the MeCP2 protein levels were increased in hTau‐overexpressing neurons (Figure 2a,b), in the cortex of hTau transgenic mice (Figure 2d,e) and in the brains of AD patients (Figure 2g,h) but that the mRNA levels were unchanged (Figure 2c,f), which indicates that the upregulation of MeCP2 induced by tau overexpression occurs posttranscriptionally. The gene discussed is MAPT; the disease is Alzheimer disease.